(Q38120295)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

title

The preclinical profile of lurasidone: clinical relevance for the treatment of schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

0 references

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

author name string

Frank I Tarazi

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

language of work or name

English

0 references

publication date

10 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Drug Discovery

4 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

4 March 2020

page(s)

1297-1307

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23837554%20AND%20SRC:MED&resulttype=core&format=json

Iloperidone, asenapine and lurasidone: a primer on their current status

4 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Lurasidone: a new drug in development for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

A new computer-assisted two-way avoidance conditioning equipment for rats: behavioral and pharmacological validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Modeling the positive symptoms of schizophrenia in genetically modified mice: pharmacology and methodology aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Effects of haloperidol, sulpiride and SCH 23390 on passive avoidance learning in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The muscarinic receptor agonist BuTAC, a novel potential antipsychotic, does not impair learning and memory in mouse passive avoidance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Lurasidone (SM-13496), a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Analysis of the role of 5-HT1A receptors in spatial and aversive learning in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze tests in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Pre-Injury magnesium treatment prevents traumatic brain injury-induced hippocampal ERK activation, neuronal loss, and cognitive dysfunction in the radial-arm maze test

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Cognition in schizophrenia: core psychological and neural mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The role of 5-hydroxytryptamine 7 receptors in the phencyclidine-induced novel object recognition deficit in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The role of serotonin receptors in the action of atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Impaired performance on the object retrieval-detour test of executive function in the SIV/macaque model of AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Contrasting effects of excitotoxic lesions of the prefrontal cortex on the behavioural response to D-amphetamine and presynaptic and postsynaptic measures of striatal dopamine function in monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Humans and natural predators induce different fear/anxiety reactions and response pattern to diazepam in marmoset monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Effects of lurasidone on executive function in common marmosets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Antidepressant-like effects of cytidine in the forced swim test in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Strain differences in the behavioral effects of antidepressant drugs in the rat forced swimming test.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Effects of lurasidone in behavioral models of depression. Role of the 5-HT₇ receptor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Selective blockade of 5-hydroxytryptamine (5-HT)7 receptors enhances 5-HT transmission, antidepressant-like behavior, and rapid eye movement sleep suppression induced by citalopram in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The 5-HT(7) receptor as a mediator and modulator of antidepressant-like behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Evaluation of the repeated open-space swim model of depression in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Antidepressant-like action of intracerebral 6-fluoronorepinephrine, a selective full α-adrenoceptor agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Serotonin receptors involved in antidepressant effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Antipsychotic drug actions on gene modulation and signaling mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Neuroplasticity signaling pathways linked to the pathophysiology of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Reductions in neurotrophin receptor mRNAs in the prefrontal cortex of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Distinct role of long 3' UTR BDNF mRNA in spine morphology and synaptic plasticity in hippocampal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Induction of fear extinction with hippocampal-infralimbic BDNF

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Learning under stress: how does it work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Epigenetic regulation of BDNF gene transcription in the consolidation of fear memory

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Strategies for maximizing clinical effectiveness in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Adjunctive psychosocial therapies for the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

New treatment guidelines for acute bipolar mania: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Efficacy of pharmacotherapy in bipolar disorder: a report by the WPA section on pharmacopsychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Linking molecules to mood: new insight into the biology of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Modulation of neuronal plasticity following chronic concomitant administration of the novel antipsychotic lurasidone with the mood stabilizer valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Histone deacetylase 5 epigenetically controls behavioral adaptations to chronic emotional stimuli

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Neuronal plasticity: a link between stress and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Antistress properties of antidepressant drugs and their clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Conserved role for the serotonin transporter gene in rat and mouse neurobehavioral endophenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

A study in male and female 5-HT transporter knockout rats: an animal model for anxiety and depression disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Long-Term duloxetine treatment normalizes altered brain-derived neurotrophic factor expression in serotonin transporter knockout rats through the modulation of specific neurotrophin isoforms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Reduced function of the serotonin transporter is associated with decreased expression of BDNF in rodents as well as in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Neuronal activity-induced Gadd45b promotes epigenetic DNA demethylation and adult neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Growth arrest and DNA-damage-inducible, beta (GADD45b)-mediated DNA demethylation in major psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance spectroscopy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Critical role of promoter IV-driven BDNF transcription in GABAergic transmission and synaptic plasticity in the prefrontal cortex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The preclinical profile of asenapine: clinical relevance for the treatment of schizophrenia and bipolar mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Antipsychotics in pediatric and adolescent patients: a review of comparative safety data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

5-HT7, neurogenesis and antidepressants: a promising therapeutic axis for treating depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Pharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Therapeutic options for treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

A novel augmentation strategy for treating resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

The serotonin-1A receptor in anxiety disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

5-HT(1A) receptor function in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163

Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2013.815163